C. Michael Gibson MD· @CMichaelGibson · X·· 12 hours agoScore70
Body · original
In patients with HER2-positive advanced #breastcancer, the HER2-targeted bispecific antibody #anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of 58.5%, as compared with 34.4% with standard therapy.
#ESMO26
https://nej.md/4BcWlF3
212 views · 1 like · 1 repost · 0 replies
Conference abstracts
LBA15matched by Proffered paper 2: Breast cancer, early and advanced stage
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.orgSource: C. Michael Gibson MD · x.com